Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vizionfocus Inc. (4771.TW)
Miaoli, TW
Established in 2011 and based in Miaoli, Taiwan, Vizionfocus Inc. operates as a manufacturer of various sophisticated products. The company primarily produces medical equipment, serving key markets across Taiwan, China, Japan, and the United States. Its manufacturing capabilities also encompass mechanical equipment, optical instruments, and precision instruments. Beyond its production activities, Vizionfocus engages in global trade and delivers consultancy services. A significant area of its business involves the full lifecycle of contact lenses, from initial research and development to design, production, and wholesale distribution.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.54% | -1.06% | -5.10% | +3.33% | +5.38% | +7.51% | -11.64% | -40.58% | -40.58% | -40.58% | -40.58% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+16.2% ★ Q1'26: +27.2% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+9.5% Q1'26: +11.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+16.0% Q1'26: -13.6% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+28.9% ★ Q1'26: +28.9% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+17.1% ★ Q1'26: +18.1% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+8.0% Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×1.58× Q1'26: 0.97× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
2.57B
est: 2.57B (+0.0%)
|
3.00B
est: 3.02B (-0.6%)
|
3.49B
est: 3.50B (-0.4%)
|
4.34B
4.23B – 4.44B
+24.1% YoY
|
4.98B
4.92B – 5.03B
+14.7% YoY
|
5.30B
5.24B – 5.36B
+6.4% YoY
|
| EBITDA |
1.13B
est: 1.02B (+11.4%)
|
1.30B
est: 1.16B (+12.2%)
|
1.01B
est: 1.35B (-25.3%)
|
1.67B
1.63B – 1.71B
+24.1% YoY
|
1.92B
1.89B – 1.94B
+14.7% YoY
|
2.04B
2.02B – 2.06B
+6.4% YoY
|
| EBIT |
854.47M
est: 690.42M (+23.8%)
|
949.15M
est: 1.08B (-11.8%)
|
1.01B
est: 1.25B (-19.3%)
|
1.55B
1.51B – 1.58B
+24.1% YoY
|
1.78B
1.75B – 1.79B
+14.7% YoY
|
1.89B
1.87B – 1.91B
+6.4% YoY
|
| Net Income |
562.28M
est: 630.75M (-10.9%)
|
669.59M
est: 722.76M (-7.4%)
|
807.94M
est: 801.90M (+0.8%)
|
1.01B
993.64M – 1.03B
+26.3% YoY
|
1.22B
1.21B – 1.24B
+20.9% YoY
|
1.31B
1.28B – 1.32B
+6.6% YoY
|
| SGA |
66.10M
est: 151.56M (-56.4%)
|
161.59M
est: 126.10M (+28.1%)
|
—
est: 146.17M (-100.0%)
|
181.34M
176.60M – 185.15M
+24.1% YoY
|
208.02M
205.40M – 210.12M
+14.7% YoY
|
221.39M
218.61M – 223.63M
+6.4% YoY
|
| EPS |
10.77
est: 10.72 (+0.5%)
|
11.81
est: 11.37 (+3.9%)
|
12.71
est: 12.61 (+0.8%)
|
15.95
15.63 – 16.24
+26.4% YoY
|
19.29
18.97 – 19.54
+21.0% YoY
|
20.53
20.19 – 20.80
+6.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.02% | 26.6K | 0.42% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 112.0K | 0.65% |
| 3 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.01% | 25.8K | 0.35% |
| 4 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.01% | 26.6K | 0.33% |
| 5 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.01% | 13.3K | 0.33% |
| 6 | Avantis Emerging Markets Value ETF AVES | 0.00% | 66.5K | 0.36% |
| 7 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 87.0K | 0.46% |
| 8 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 334.8K | 0.39% |
| 9 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 6.7K | 0.56% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 173.4K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| An Shi | General Manager & Director | — | male |
| Chia-Hua Chang | General Manager of Vizionfocus Inc., (Jiang Su) | — | — |
| Peter Su | Chief Information Security Officer | — | — |
| Sofia Lee | Chief Financial Officer & Corporate Governance Officer | — | — |
| Xingjuan Li | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4771.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
